Pfizer used one of its footnotes in the Q1 report to sweep out an experimental Huntington’s drug that failed recently in a Phase II trial, the latest in a long series of implosions in the neuroscience field.
Pfizer didn’t explain what went wrong for PF-02545920, but in a blog post at HDBuzz in December, which was edited by one of the investigators in the study, the drug was written off as a complete flop in improving the ability of patients to function better — or boost scores on any other symptoms evaluated in the 271-patient trial.
“We’re all very disappointed that the study drug didn’t meet its primary endpoint of improving movements in HD, or any of the secondary endpoints looking at other features of the disease,” study leader Marielle Delnomdedieu told Ed Wild, who wrote the piece. “But despite the negative outcome, we’ve learned a great deal about Huntington’s disease and PDE10. The trial data will be a rich resource for HD research. We’re pleased with the way the trial was planned and run, and immensely grateful to the patients and their relatives involved in the trial.”
PDE10 is believed to be involved on cell signaling, and some investigators believe a drug could help safeguard pateints’ brain cells and improve patients ability to counteract the disease.
Get Endpoints News in your inbox
News reports for those who discover, develop, and market drugs. Join 16,000+ biopharma pros who read Endpoints News articles by email every day. Free subscription.
You're subscribing to Endpoints News
John Carroll, Editor and Co-Founder
We produce two daily newsletters designed to give you a complete picture of what's important in biopharma.